Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence

Pharmacological Research

Volumn 113, Issue , 2016, Pages 276-289

  Avagliano, Carmen ^a   Russo, Roberto ^a   De Caro, Carmen ^a   Cristiano, Claudia ^a   La Rana, Giovanna ^a   Piegari, Giuseppe ^a   Paciello, Orlando ^a   Citraro, Rita ^b   Russo, Emilio ^b   De Sarro, Giovambattista ^b   Meli, Rosaria ^a   Mattace Raso, Giuseppina ^a   Calignano, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Apoptosis; Endoplasmic reticulum stress; Oxidative stress; Palmitoylethanolamide; Parkinson's disease; PPAR

Indexed keywords

CYCLOOXYGENASE 2; GLUCOSE REGULATED PROTEIN 78; INDUCIBLE NITRIC OXIDE SYNTHASE; INITIATION FACTOR 2ALPHA; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE; DOPAMINE; ETHANOLAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE; OXIDOPAMINE; PALMITIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; BRAIN LEVEL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL LINE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SH SY5Y CELL LINE; UNFOLDED PROTEIN RESPONSE; ANIMAL; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NEUROBLASTOMA; TOXICITY AND INTOXICATION;

ANIMALS; APOPTOSIS; CELL DEATH; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; ENDOPLASMIC RETICULUM STRESS; ETHANOLAMINES; MALE; MICE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; OXIDOPAMINE; PALMITIC ACIDS; PPAR ALPHA; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE;

EID: 84986271121     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.004     Document Type: Article

References (58)

1. [1] Calì, T., Ottolini, D., Brini, M., Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. Biofactors 37 (2011), 228–240.
2. [2] Mercado, G., Valdés, P., Hetz, C., An ERcentric view of Parkinson's disease. Trends Mol. Med. 19 (2013), 165–175.
3. [3] Roussel, B.D., Kruppa, A.J., Miranda, E., Crowther, D.C., Lomas, D.A., Marciniak, S.J., Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 12 (2013), 105–118.
4. [4] Rao, R.V., Bredesen, D.E., Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr. Opin. Cell Biol. 16 (2004), 653–662.
5. [5] Kozutsumi, Y., Segal, M., Normington, K., Gething, M.J., Sambrook, J., The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 332 (1988), 462–464.
6. [6] Szegezdi, E., MacDonald, D.C., Ni Chonghaile, T., Gupta, S., Samali, A., Bcl-2 family on guard at the ER. Am. J. Physiol. Cell Physiol. 296 (2009), 941–953.
7. [7] Gupta, S., Cuffe, L., Szegezdi, E., Logue, S.E., Neary, C., Healy, S., Samali, A., Mechanisms of ER stress-mediated mitochondrial membrane permeabilization. Int. J. Cell Biol., 2010, 2010, 170215.
8. [8] Ryu, E.J., Harding, H.P., Angelastro, J.M., Vitolo, O.V., Ron, D., Greene, L.A., Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 22 (2002), 10690–10698.
9. [9] Blum, D., Torch, S., Lambeng, N., Nissou, N., Benabid, A.L., Sadoul, R., Verna, J.M., Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001), 135–172.
10. [10] Hwang, Y.P., Jeong, H.G., The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett. 23 (2008), 2655–2662.
11. [11] D'Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., Calignano, A., Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37 (2012), 1784–1792.
12. [12] Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., Cuzzocrea, S., Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One, 7, 2012, e41880.
13. [13] Kreisler, A., Gelé, P., Wiart, J.F., Lhermitte, M., Destée, A., Bordet, R., Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res. 1135 (2007), 77–84.
14. [14] Moreno, S., Farioli-Vecchioli, S., Ceru, M.P., Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004), 131–145.
15. [15] Galan-Rodriguez, B., Suarez, J., Gonzalez-Aparicio, R., Bermudez-Silva, F.J., Maldonado, R., Robledo, P., Rodriguez de Fonseca, F., Fernandez-Espejo, E., Oleoylethanolamide exerts partial and dosedependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 56 (2009), 653–664.
16. [16] Bandiera, T., Ponzano, S., Piomelli, D., Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol. Res. 86 (2014), 11–17.
17. [17] Blankman, J.L., Cravatt, B.F., Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65 (2013), 849–871.
18. [18] Tsuboi, K., Takezaki, N., Ueda, N., The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem. Biodivers. 4 (2007), 1914–1925.
19. [19] Ferrer, B., Asbrock, N., Kathuria, S., Piomelli, D., Giuffrida, A., Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 18 (2003), 1607–1614.
20. [20] Giuffrida, A., McMahon, L.R., In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat. 91 (2010), 90–103.
21. [21] Skaper, S.D., Facci, L., Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 (2012), 3312–3325.
22. [22] Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S.D., Leon, A., Mastcells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 3376–3380.
23. [23] Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., Piomelli, D., The nuclear receptor peroxisome proliferator-activated receptor alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 (2005), 15–19.
24. [24] Lo Verme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., Piomelli, D., Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319 (2006), 1051–1061.
25. [25] Franklin, K.G.J., Paxinos, G., The Mouse Brain in Stereotaxic Coordinates. 1997, Academic Press.
26. [26] Påhlman, S., Ruusala, A.I., Abrahamsson, L., Mattsson, M.E., Esscher, T., Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ. 14 (1984), 135–144.
27. [27] Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Ceña, V., Gallego, C., Comella, J.X., Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 75 (2000), 991–1003.
28. [28] Artamonov, M., Zhukov, O., Shuba, I., Storozhuk, L., Khmel, T., Klimashevsky, V., Mikosha, A., Gula, N., Incorporation of labelled N-acylethanolamine (NAE) into rat brain regions in vivo and adaptive properties of saturated NAE under x-ray irradiation. Ukr. Biokhim. Zh. 77:1999 (2005), 51–62.
29. [29] Grillo, S.L., Keereetaweep, J., Grillo, M.A., Chapman, K.D., Koulen, P., N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids. Drug Des. Dev. Ther. 7 (2013), 747–752.
30. [30] Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Höglinger, G.U., Oertel, W.H., Hartmann, A., Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 210 (2008), 182–193.
31. [31] Pitcher, T.L., Melzer, T.R., MacAskill, M.R., Graham, C.F., Livingston, L., Keenan, R.J., Watts, R., Dalrymple-Alford, J.C., Anderson, T.J., Reduced striatal volumes in Parkinson's disease: a magnetic resonance imaging study. Transl. Neurodegener. 21 (2012), 1–17.
32. [32] Bugiani, O., Perdelli, F., Salvarani, S., Leonardi, A., Mancardi, G.L., Loss of striatal neurons in Parkinson's disease: a cytometric study. Eur. Neurol. 19 (1980), 339–344.
33. [33] Simola, N., Morelli, M., Carta, A.R., The 6-Hydroxydopamine model of parkinson's disease. Neurotox. Res. 11 (2007), 151–167.
34. [34] Soto-Otero, R., Méndez-Alvarez, E., Hermida-Ameijeiras, A., Muñoz-Patiño, A.M., Labandeira-Garcia, J.L., Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some anti-oxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74 (2000), 1605–1612.
35. [35] Debeir, T., Ginestet, L., François, C., Laurens, S., Martel, J.C., Chopin, P., Marien, M., Colpaert, F., Raisman-Vozari, R., Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp. Neurol. 193 (2005), 444–454.
36. [36] Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H., Przedborski, S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci 22 (2002), 1763–1771.
37. [37] Gao, H.-M., Jiang, J., Wilson, B., Zhang, W., Hong, J.-S., Liu, B., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002), 1285–1297.
38. [38] Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999), 1403–1409.
39. [39] Rodrigues, R.W.P., Gomide, V.C., Chadi, G., Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Int. J. Neurosci. 109 (2001), 91–126.
40. [40] Mattace Raso, G., Russo, R., Calignano, A., Meli, R., Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 86 (2014), 32–41.
41. [41] D'Agostino, G., La Rana, G., Russo, R., Sasso, O., Iacono, A., Esposito, E., Mattace Raso, G., Cuzzocrea, S., Lo Verme, J., Piomelli, D., Meli, R., Calignano, A., Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 613 (2009), 54–59.
42. [42] Mattace Raso, G., Esposito, E., Vitiello, S., Iacono, A., Santoro, A., D'Agostino, G., Sasso, O., Russo, R., Piazza, P.V., Calignano, A., Meli, R., Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α. J. Neuroendocrinol. 23 (2011), 591–600.
43. [43] Tamatani, M., Che, Y.H., Matsuzaki, H., Ogawa, S., Okado, H., Miyake, S., Mizuno, T., Tohyama, M., Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF kappa B activation in primary hippocampal neurons. J. Biol. Chem. 274 (1999), 8531–8538.
44. [44] Zhou, C., Huang, Y., Przedborski, S., Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 1147 (2008), 93–104.
45. [45] Graham, D.G., Tiffany, S.M., Bell, W.R. Jr., Gutknecht, W.F., Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978), 644–653.
46. [46] Bove, J., Perier, C., Neurotoxin-based models of Parkinson's disease. Neuroscience 211 (2011), 51–76.
47. [47] Glinka, Y., Gassen, M., Youdim, M.B., Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. Suppl. 50 (1997), 55–66.
48. [48] Kumar, R., Agarwal, A.K., Seth, P.K., Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64 (1995), 1703–1707.
49. [49] Soto-Otero, R., Mendez-Alvarez, E., Hermida-Ameijeiras, A., Munoz-Patino, A.M., Labandeira-Garcia, J.L., Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem 74 (2000), 1605–1617.
50. [50] Mattace Raso, G., Simeoli, R., Russo, R., Santoro, A., Pirozzi, C., d'Emmanuele di Villa Bianca, R., Mitidieri, E., Paciello, O., Pagano, T.B., Orefice, N.S., Meli, R., Calignano, A., N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. Pharmacol. Res. 76 (2013), 67–76.
51. [51] Inoue, I., Goto, S., Matsunaga, T., Nakajima, T., Awata, T., Hokari, S., Komoda, T., Katayama, S., The ligands/activators for peroxisome proliferators-activated receptor alpha (PPAR alpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50 (2001), 3–11.
52. [52] Cullinan, S.B., Diehl, J.A., Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int. J. Biochem. Cell Biol. 38 (2006), 317–332.
53. [53] Malhotra, J.D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S.W., Kaufman, R.J., Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 18525–18530.
54. [54] Ryu, E.J., Harding, H.P., Angelastro, J.M., Vitolo, O.V., Ron, D., Greene, L.A., Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 22 (2002), 10690–10698.
55. [55] Holtz, W.A., O'Malley, K.L., Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem. 278 (2003), 19367–19377.
56. [56] Hoozemans, J.J., van Haastert, E.S., Eikelenboom, P., de Vos, R.A., Rozemuller, J.M., Scheper, W., Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354 (2007), 707–711.
57. [57] Takahashi, T., Deng, Y., Maruyama, W., Dostert, P., Kawai, M., Naoi, M., Uptake of a neurotoxin-candidate (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J. Neural Transm. Gen. Sect. 98 (1994), 107–118.
58. [58] Luo, F., Wei, L., Sun, C., Chen, X., Wang, T., Li, Y., Liu, Z., Chen, Z., Xu, P., HtrA2/Omi is involved in 6-OHDA-induced endoplasmic reticulum stress in SH-SY5Y cells. J. Mol. Neurosci. 47 (2012), 120–127.